<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057481</url>
  </required_header>
  <id_info>
    <org_study_id>17300600</org_study_id>
    <nct_id>NCT05057481</nct_id>
  </id_info>
  <brief_title>Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus</brief_title>
  <official_title>Reappraisal of Second-line Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a deficiency in guidelines about the treatment of autoimmune hemolytic anemia in&#xD;
      systemic lupus erythematosus (SLE), especially in refractory cases. Mycophenolate mofetil&#xD;
      (MMF) showed promising results in those patients but still, the data available are in form of&#xD;
      case reports. So, investigators will investigate the efficiency of MMF against a&#xD;
      well-established treatment Rituximab in the treatment of refractory autoimmune hemolytic&#xD;
      anemia in SLE patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a deficiency in guidelines about the treatment of autoimmune hemolytic anemia in&#xD;
      systemic lupus erythematosus (SLE), especially in refractory cases. Mycophenolate mofetil&#xD;
      (MMF) showed promising results in those patients but still, the data available are in form of&#xD;
      case reports. So, the investigators will investigate the efficiency of MMF against a&#xD;
      well-established treatment Rituximab in the treatment of refractory autoimmune hemolytic&#xD;
      anemia in SLE patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response (CR) proportion</measure>
    <time_frame>12 weeks</time_frame>
    <description>CR defined as hemoglobin &gt; 12 g/dL not attributed to transfusion effect and the normalization of hemolytic markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>partial response (PR) proportion</measure>
    <time_frame>12 weeks</time_frame>
    <description>PR defined as hemoglobin 10-12 g/dL or at least â‰¥ 2 g/dL increase from baseline not attributed to transfusion effect and the normalization of hemolytic markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>rate of occurrence of adverse events of the both drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) sub-scale questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>MMF arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil 500mg</intervention_name>
    <description>MMF 2gram/day orally for 12 weeks</description>
    <arm_group_label>MMF arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 of rituximab given intravenously weekly for 4 weeks.</description>
    <arm_group_label>Rituximab arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of erythematosus (SLE) according to The American College of Rheumatology&#xD;
             (ACR) and the European League Against Rheumatism (EULAR) guidelines.&#xD;
&#xD;
          -  secondary autoimmune hemolytic anemia (AIHA) that does not respond properly to&#xD;
             corticosteroid or when the patients are intolerant to treatment, or refuse standard&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  any contraindication of the used drugs.&#xD;
&#xD;
          -  any known hypersensitivity of the used drugs.&#xD;
&#xD;
          -  congenital hemolytic anemia.&#xD;
&#xD;
          -  chronic renal failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>faculty of medicine, Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>17111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Eman Mohammed Ibrahem Kamel</investigator_full_name>
    <investigator_title>lecturer in internal medicine department of faculty of medicine,Assiut university</investigator_title>
  </responsible_party>
  <keyword>autoimmune hemolytic anemia</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

